| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | N/A | N/A | N/A | N/A | N/A |
| MA10 | N/A | N/A | N/A | N/A | N/A |
| MA20 | N/A | N/A | N/A | N/A | N/A |
| MA50 | N/A | N/A | N/A | N/A | N/A |
| MA100 | N/A | N/A | N/A | N/A | N/A |
| MA200 | N/A | N/A | N/A | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | N/A | N/A | N/A | N/A | N/A |
| RSI | N/A | N/A | N/A | N/A | N/A |
| STOCH | N/A | N/A | N/A | N/A | N/A |
| WILL %R | N/A | N/A | N/A | N/A | N/A |
| CCI | N/A | N/A | N/A | N/A | N/A |
|
Monday, July 27, 2026 01:12 PM
Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan ...
|
|
Friday, July 24, 2026 11:45 AM
Scribe Therapeutics (NASDAQ:SCTX), a clinical-stage developer of gene therapies for heart disease, surged 67% on Friday after raising $128.7 million in an upsized initial public offering. The Alameda, ...
|
|
Friday, July 24, 2026 10:35 AM
Scribe Therapeutics (SCTX), a gene therapy developer whose collaborators include Sanofi (SNY) and Eli Lilly (LLY), rose nearly 50% in its first trading session as a public company on Friday after an ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/07/26 | 21.48 | 22.75 | 17.305 | 18.97 | 418,351 |
|
|
||||
|
|
||||
|
|